Health and Me

Ishita Roy

FDA Greenlights Zevaskyn for Rare Genetic Skin Condition

In a landmark development for patients who live with a rare and painful skin condition, the US Food and Drug Administration or the FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa or RDEB. This is an inherited disorder that causes the skin to be extremely fragile. I also leads to chronic wounds, bleeding, and tearing even from minor friction or trauma. 

As per the 2015 study published in the Journal of Clinical and Aesthetic Dermatology, there are four major subtypes of the <span>skin disorder</span>, which comes from the heterogeneous group of inherited mechanobullous disorder hat is caused by mutation in genes that encode structural proteins in the skin. The overall condition is referred to as epidermolysis bullosa, and one of its type is RDEB, which further comes with two main subtypes of dystrophic EB. 

Zevaskyn is now the first and only autologous cell-based gene therapy approved for both adult and pediatric patients living with this life-altering condition.

Why Is This A Breakthrough In Gene Therapy?

Zevaskyn represents a new era in wound care and gene therapy. Unlike traditional treatments that only manage symptoms, this one-time surgical application targets the underlying genetic mutation responsible for RDEB. The therapy uses the patient's own skin cells, which are genetically modified to produce a functional version of the missing COL7A1 gene, critical for anchoring skin layers together.

"Zevaskyn is not just a bandage—it’s a breakthrough that may help change the course of this disease for many," said Madhav Vasanthavada, Ph.D., Chief Commercial Officer at Abeona Therapeutics, the biopharmaceutical company behind the treatment.

The FDA based its approval from the results of two clinical trials: a phase 1/2a study and the pivotal phase 3 VITAL study. 

Phase 1/2a Trial: In this study, seven patients with 38 chronic wounds received a single Zevaskyn application. Researchers observed a significant and long lasting improvement at treated sites during the median follow-up of seven years. 

Phase 3 VITAL Study: This was a larger study that included 43 patients with large unhealed or non healing wounds. After six months, 81% of those wounds treated by Zevaskyn, showed at least 50% healing, as compared to only 16% in the control group, who had received the standard care. 

These outcomes were not only statistically significant but also clinically meaningful, especially for patients who have previously struggled with limited treatment options.

Zevaskyn also showed a favorable safety profile across both studies. No treatment-related serious adverse events were reported. The most common minor side effects were procedural pain and itching, affecting approximately 5% of participants.

"This therapy offers hope for patients and families who have lived too long without effective solutions," said Vasanthavada. “We’re confident in Zevaskyn’s ability to deliver long-term results and are committed to making it widely accessible.”

To ensure access, Abeona Therapeutics plans to collaborate with both commercial insurers and government payers. The company aims to develop outcome-based agreements that reflect the long-term benefits of a single application of Zevaskyn, reducing the need for repeat procedures or ongoing wound care costs.

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.

Health Conditions A-Z

health

skin and hair

skincare

skin disease

skin disorder

health news

COVID-19 Update: 257 Active Cases In India, 2 New Deaths In Mumbai

What Is Japanese Walk—The Fitness Trend That Makes You 10 Years Younger

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection

Health News

Must-Do Chest Exercises You Can Try At Home

What Are The Symptoms Of JN.1 COVID-19 Strain?

Why Does Sleeping Become Harder As You Age?

High-Fiber Healthy Drinks You Should Try

10 Dumbbell Exercise Variations For Upper-Body Strength

A Parent’s Guide To Pets: Important Points To Consider For Your Child’s Health

Food Anxiety Is Real – How Your Food Intake Affects Your Anxiety

World Osteoporosis Month: Ways To Strengthen Your Bones

Brain Exercises To Keep You Cognitively Sharp

Easy Recipes To Make When You Don’t Wish To Cook

Physical Signs Of High Cortisol

9 Healthy Plant-Based Protein Rich Dishes To Try

What Happens When You Have Low Blood Pressure?

Throw These Toxic Bathroom Items Away To Protect Your Health

This Is What Cricket Superstar Virat Kohli Eats In A Day

Signs You Are Experiencing Sensory Overload

Shoulder Exercises You Should Do For Defined Shoulders

Best Foods To Eat When You Are Fasting

​Ghee For Ayurveda: Why It Should Be A Part Of Your Diet​

Symptoms Of Ovarian Cancer You Should Know

Yoga Poses That Can Build Core Strength

Biotin-Rich Foods You Should Add To Your Diet

Unexpected Physical Signs Of Stress

Simple And Affective Guide To Stop A Panic Attack

Signs Of Heat Exhaustion In Children

10 Heart Symptoms You Shouldn't Ignore

Lower Your Cholesterol With These Foods

Food Myths You Should Stop Believing

Work Stressing You Out? Tips To Handle Toxic Workspaces

Looking To Gain Weight? High-Calorie Healthy Foods To Try

​Pomegranates Are A Must For Summer, Here’s Why​

​How Does Being A Night Owl Change Your Brain​

​Can Nightlights Affect Your Child’s Sleep​

How To Decide Whether You Should Do Cardio Or Strength Training?

Enjoying Hobbies As An Adult Is More Important Than You Realize

Screentime Matters For Parents Too, Here's How It Causes Issues

Why Should We Discard Expired Prescription Drugs?

Perks Of Having Home Plants For Your Health

Signs You Are Dealing With Depleted Mother Syndrome

Protein-Rich Fruit Smoothies You Must Try

In a landmark development for patients who live with a rare and painful skin condition, the US Food and Drug Administration or the FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa or RDEB. This is an inherited disorder that causes the skin to be extremely fragile. I also leads to chronic wounds, bleeding, and tearing even from minor friction or trauma. As per the 2015 study published in the Journal of Clinical and Aesthetic Dermatology, there are four major subtypes of the skin disorder, which comes from the heterogeneous group of inherited mechanobullous disorder hat is caused by mutation in genes that encode structural proteins in the skin. The overall condition is referred to as epidermolysis bullosa, and one of its type is RDEB, which further comes with two main subtypes of dystrophic EB. Zevaskyn is now the first and only autologous cell-based gene therapy approved for both adult and pediatric patients living with this life-altering condition.Why Is This A Breakthrough In Gene Therapy?Zevaskyn represents a new era in wound care and gene therapy. Unlike traditional treatments that only manage symptoms, this one-time surgical application targets the underlying genetic mutation responsible for RDEB. The therapy uses the patient's own skin cells, which are genetically modified to produce a functional version of the missing COL7A1 gene, critical for anchoring skin layers together."Zevaskyn is not just a bandage—it’s a breakthrough that may help change the course of this disease for many," said Madhav Vasanthavada, Ph.D., Chief Commercial Officer at Abeona Therapeutics, the biopharmaceutical company behind the treatment.How Was It Approved?The FDA based its approval from the results of two clinical trials: a phase 1/2a study and the pivotal phase 3 VITAL study. Phase 1/2a Trial: In this study, seven patients with 38 chronic wounds received a single Zevaskyn application. Researchers observed a significant and long lasting improvement at treated sites during the median follow-up of seven years. Phase 3 VITAL Study: This was a larger study that included 43 patients with large unhealed or non healing wounds. After six months, 81% of those wounds treated by Zevaskyn, showed at least 50% healing, as compared to only 16% in the control group, who had received the standard care. These outcomes were not only statistically significant but also clinically meaningful, especially for patients who have previously struggled with limited treatment options.Zevaskyn also showed a favorable safety profile across both studies. No treatment-related serious adverse events were reported. The most common minor side effects were procedural pain and itching, affecting approximately 5% of participants."This therapy offers hope for patients and families who have lived too long without effective solutions," said Vasanthavada. “We’re confident in Zevaskyn’s ability to deliver long-term results and are committed to making it widely accessible.”Access For PatientsTo ensure access, Abeona Therapeutics plans to collaborate with both commercial insurers and government payers. The company aims to develop outcome-based agreements that reflect the long-term benefits of a single application of Zevaskyn, reducing the need for repeat procedures or ongoing wound care costs.With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.

fda greenlights zevaskyn for rare genetic skin condition

Aarushi Bhadury

Covid Cases Surge In Singapore: What Do We Know About The New Variant On The Loose?

covid cases surge in singapore: what do we know about the new variant on the loose?

FDA Approves New COVID Vaccine But Not Everyone Qualifies

fda approves new covid vaccine but not everyone qualifies

Longest Covid Infection Reported Lasted 505 Days Nonstop; What Are Persistent Infections?

longest covid infection reported lasted 505 days nonstop; what are persistent infections?

Health & Wellness

Severe Pneumonia Shows 'Differently' In Children, Study Reveals New Models To Help Doctors Distinguish

study reveals new models to help doctors distinguish severe pneumonia in children

Coronavirus epidemic, that is responsible for millions of deaths worldwide, has resurged. With cases rising in countries like India, Singapore and Hong Kong, experts have warned against the new JN.1 variant of Omicron, which is causing the current spike. Notably, as of May 2025, scientists have identified thousands of SARS-CoV-2 variants through global genomic surveillance.

India is battling the epidemic surge too, with 257 active cases and two <span>COVID-19</span> related deaths. Kerala has the most cases with 69, followed by Maharashtra with 44, and Tamil Nadu with 34. Other states such as Karnataka, Gujarat, Delhi, Haryana, Rajasthan, and Sikkim have also reported new infections. The two COVID-19 related deaths have been confirmed at KEM Hospital in Mumbai, causing some concern locally in that area. Health experts from important groups like ICMR and NCDC have stated that India's overall situation is still under control. 

Health experts from important groups like the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC) have stated that India's overall situation is still under control. 

<h2>What Is JN.1 Variant of Omicron? </h2>

According to John Hopkins School of Public Health, new COVID-19 variant called BA.2.86, which is a sub-variant of Omicron appeared in late 2023. Scientists noticed it because it had around 30 more changes, or mutations, than other variants. These mutations helped it to better avoid our body's defenses, or immunity. However, BA.2.86 never became the most common variant in late summer or early fall of 2023. 

Now, a new variant called JN.1 has emerged. It's a "child" of BA.2.86. JN.1 has one or two new mutations that make it spread more easily. So, it can still avoid our immunity like its parent, but it's now better at getting from person to person. The symptoms people are experiencing with the current <span>COVID</span> wave are a bit different. While cough and sore throat are still common, some new symptoms include nausea, vomiting, brain fog, and eye irritation (conjunctivitis). 

According to John Hopkins School of Public Health, new COVID-19 variant called BA.2.86, which is a sub-variant of Omicron appeared in late 2023. Scientists noticed it because it had around 30 more changes, or mutations, than other variants. These mutations helped it to better avoid our body's defenses, or immunity. 

However, BA.2.86 never became the most common variant in late summer or early fall of 2023. Now, a new variant called JN.1 has emerged. It's a "child" of BA.2.86. JN.1 has one or two new mutations that make it spread more easily. So, it can still avoid our immunity like its parent, but it's now better at getting from person to person. The symptoms people are experiencing with the current COVID wave are a bit different. While cough and sore throat are still common, some new symptoms include nausea, vomiting, brain fog, and eye irritation (conjunctivitis). 

<h2>Core Preventive Strategies For COVID-19 </h2>

While there have been no urgent changes to the guidelines regarding preventive measures of covid, here are the core strategies for prevention one must partake in according to the Centers Of Disease Control and Prevention. 

Get all recommended COVID-19 vaccine doses. While vaccinated people can still get sick, staying current with your shots significantly lowers your risk of becoming severely ill, needing hospital care, or dying from COVID-19. 

Regularly wash your hands and maintain overall cleanliness. This simple practice helps reduce the spread of germs, including the virus that causes COVID-19. 

Take steps to ensure cleaner air in indoor spaces. This could involve using air purifiers or opening windows to improve ventilation, which helps reduce airborne virus particles. 

If you have symptoms like a cough or fever, stay home and avoid contact with others, even those you live with who are not sick. This prevents the virus from spreading further. 

<h4>Know When to Return to Activities </h4>

Understand the guidelines for when it's safe to resume your normal daily activities after being sick. This ensures you're no longer a risk to others. 

Wearing a mask and keeping a physical distance from others can further reduce the risk of catching or spreading COVID-19. These are extra layers of protection you can choose to use. 

If you have factors that put you at higher risk for severe illness, get tested and seek treatment quickly. Early treatment can significantly lower your risk of serious illness, but it must be started within a few days of symptoms appearing. 

COVID

singapore covid 19 cases india

corona news today

corona cases in india today

coronavirus india

corona cases

covid 19 cases in india

COVID-19

Coronavirus epidemic, that is responsible for millions of deaths worldwide, has resurged. With cases rising in countries like India, Singapore and Hong Kong, experts have warned against the new JN.1 variant of Omicron, which is causing the current spike. Notably, as of May 2025, scientists have identified thousands of SARS-CoV-2 variants through global genomic surveillance.India is battling the epidemic surge too, with 257 active cases and two COVID-19 related deaths. Kerala has the most cases with 69, followed by Maharashtra with 44, and Tamil Nadu with 34. Other states such as Karnataka, Gujarat, Delhi, Haryana, Rajasthan, and Sikkim have also reported new infections. The two COVID-19 related deaths have been confirmed at KEM Hospital in Mumbai, causing some concern locally in that area. Health experts from important groups like ICMR and NCDC have stated that India's overall situation is still under control. Health experts from important groups like the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC) have stated that India's overall situation is still under control. What Is JN.1 Variant of Omicron? According to John Hopkins School of Public Health, new COVID-19 variant called BA.2.86, which is a sub-variant of Omicron appeared in late 2023. Scientists noticed it because it had around 30 more changes, or mutations, than other variants. These mutations helped it to better avoid our body's defenses, or immunity. However, BA.2.86 never became the most common variant in late summer or early fall of 2023. Now, a new variant called JN.1 has emerged. It's a "child" of BA.2.86. JN.1 has one or two new mutations that make it spread more easily. So, it can still avoid our immunity like its parent, but it's now better at getting from person to person. The symptoms people are experiencing with the current COVID wave are a bit different. While cough and sore throat are still common, some new symptoms include nausea, vomiting, brain fog, and eye irritation (conjunctivitis). State Of COVID –19 Globally According to John Hopkins School of Public Health, new COVID-19 variant called BA.2.86, which is a sub-variant of Omicron appeared in late 2023. Scientists noticed it because it had around 30 more changes, or mutations, than other variants. These mutations helped it to better avoid our body's defenses, or immunity. However, BA.2.86 never became the most common variant in late summer or early fall of 2023. Now, a new variant called JN.1 has emerged. It's a "child" of BA.2.86. JN.1 has one or two new mutations that make it spread more easily. So, it can still avoid our immunity like its parent, but it's now better at getting from person to person. The symptoms people are experiencing with the current COVID wave are a bit different. While cough and sore throat are still common, some new symptoms include nausea, vomiting, brain fog, and eye irritation (conjunctivitis). Core Preventive Strategies For COVID-19 While there have been no urgent changes to the guidelines regarding preventive measures of covid, here are the core strategies for prevention one must partake in according to the Centers Of Disease Control and Prevention. Stay Up to Date with Vaccines Get all recommended COVID-19 vaccine doses. While vaccinated people can still get sick, staying current with your shots significantly lowers your risk of becoming severely ill, needing hospital care, or dying from COVID-19. Practice Good Hygiene Regularly wash your hands and maintain overall cleanliness. This simple practice helps reduce the spread of germs, including the virus that causes COVID-19. Improve Air Quality Take steps to ensure cleaner air in indoor spaces. This could involve using air purifiers or opening windows to improve ventilation, which helps reduce airborne virus particles. Prevent Spread If you have symptoms like a cough or fever, stay home and avoid contact with others, even those you live with who are not sick. This prevents the virus from spreading further. Know When to Return to Activities Understand the guidelines for when it's safe to resume your normal daily activities after being sick. This ensures you're no longer a risk to others. Masking and Social Distancing Wearing a mask and keeping a physical distance from others can further reduce the risk of catching or spreading COVID-19. These are extra layers of protection you can choose to use. Seek Prompt Medical Care If you have factors that put you at higher risk for severe illness, get tested and seek treatment quickly. Early treatment can significantly lower your risk of serious illness, but it must be started within a few days of symptoms appearing. 

covid-19 update: 257 active cases in india, 2 new deaths in mumbai

Riya Baibhawi

Influenza Raises Heart Attack Risk By 6X– Here's Another Reason To Get Your Flu Shot

influenza raises heart attack risk by 6x– here's another reason to get your flu shot

California may be heading toward another record year of <span>Valley fever</span> infections, with early 2025 data already showing a troubling increase in reported cases. Health officials have confirmed over 3,100 infections across the state—figures that surpass last year’s numbers for the same period and nearly double those recorded in 2023.

 Valley fever, medically known as coccidioidomycosis, is a serious lung infection caused by the <em>Coccidioides</em> fungus, which thrives in the dry, dusty soils of the western U.S. California, where the disease was first identified, consistently reports the highest number of cases nationwide. If left untreated, the illness can lead to severe, long-term respiratory issues and even death if it spreads to the brain.

 “There is no question that the number of cases is enormously higher than before,” said Dr. Royce Johnson, director of the Valley Fever Institute at Kern Medical. “If you want to see me, you’d have to wait until July, and that goes for my colleagues, too,” he told NBC News, highlighting the growing strain on healthcare systems in affected regions.

 The majority of recent infections have been reported in Kern, Los Angeles, Monterey, and Fresno counties—areas long known as hotspots. But the illness is now expanding its reach. In Contra Costa County, located in the East Bay region, cases have tripled compared to 2023. Nearby Merced and San Bernardino counties are also reporting significant spikes.

 “It appears to be spreading out,” noted Gail Sondermeyer Cooksey, an epidemiologist with the California Department of Public Health.

 Valley fever infections occur when people inhale spores released into the air from soil containing <em>Coccidioides</em>. These spores can be stirred up by wind, construction, and agricultural activities. While anyone can get infected, those most at risk include people over 60, individuals with weakened immune systems, pregnant women, diabetics, and those of Black or Filipino descent. Outdoor workers also face higher exposure.

 Symptoms typically resemble those of the flu and may include fatigue, cough, fever, shortness of breath, and skin rashes. While most recover, about 10 percent develop chronic lung issues, and approximately 1 percent experience dissemination of the infection to the skin, bones, joints, or brain.

 Health experts also point to a concerning link between <strong>climate change</strong> and the disease's rising prevalence. Shifts from prolonged drought to intense rain—common in California’s recent weather patterns—create favorable conditions for the fungus to grow and later release spores as the land dries.

 “As climate change alters the timing and intensity of precipitation in California, we see longer high-risk periods for <em>Coccidioides</em> exposure,” said Simon Camponuri, a PhD researcher at the University of California, Berkeley.

 With forecasts predicting a hot and dry summer following recent floods and mudslides, health officials are bracing for continued spikes in Valley fever cases in the coming months. Public health campaigns are urging increased awareness, especially among vulnerable populations and those living in high-risk regions.

Valley Fever

US Health News

Valley Fever symptoms

How To Identify Valley Fever

California valley fever

California may be heading toward another record year of Valley fever infections, with early 2025 data already showing a troubling increase in reported cases. Health officials have confirmed over 3,100 infections across the state—figures that surpass last year’s numbers for the same period and nearly double those recorded in 2023. Valley fever, medically known as coccidioidomycosis, is a serious lung infection caused by the Coccidioides fungus, which thrives in the dry, dusty soils of the western U.S. California, where the disease was first identified, consistently reports the highest number of cases nationwide. If left untreated, the illness can lead to severe, long-term respiratory issues and even death if it spreads to the brain. “There is no question that the number of cases is enormously higher than before,” said Dr. Royce Johnson, director of the Valley Fever Institute at Kern Medical. “If you want to see me, you’d have to wait until July, and that goes for my colleagues, too,” he told NBC News, highlighting the growing strain on healthcare systems in affected regions. The majority of recent infections have been reported in Kern, Los Angeles, Monterey, and Fresno counties—areas long known as hotspots. But the illness is now expanding its reach. In Contra Costa County, located in the East Bay region, cases have tripled compared to 2023. Nearby Merced and San Bernardino counties are also reporting significant spikes. “It appears to be spreading out,” noted Gail Sondermeyer Cooksey, an epidemiologist with the California Department of Public Health. Valley fever infections occur when people inhale spores released into the air from soil containing Coccidioides. These spores can be stirred up by wind, construction, and agricultural activities. While anyone can get infected, those most at risk include people over 60, individuals with weakened immune systems, pregnant women, diabetics, and those of Black or Filipino descent. Outdoor workers also face higher exposure. Symptoms typically resemble those of the flu and may include fatigue, cough, fever, shortness of breath, and skin rashes. While most recover, about 10 percent develop chronic lung issues, and approximately 1 percent experience dissemination of the infection to the skin, bones, joints, or brain. Health experts also point to a concerning link between climate change and the disease's rising prevalence. Shifts from prolonged drought to intense rain—common in California’s recent weather patterns—create favorable conditions for the fungus to grow and later release spores as the land dries. “As climate change alters the timing and intensity of precipitation in California, we see longer high-risk periods for Coccidioides exposure,” said Simon Camponuri, a PhD researcher at the University of California, Berkeley. With forecasts predicting a hot and dry summer following recent floods and mudslides, health officials are bracing for continued spikes in Valley fever cases in the coming months. Public health campaigns are urging increased awareness, especially among vulnerable populations and those living in high-risk regions.

valley fever cases surge in california-how to identifiy this lung infection

Tanya Dutt

GLP-1 Drugs Fight Fat, Curb Appetite And May Also Reduce Cancer Risk

Nutrition

Ozempic Without The Side Effects? Try This Drug-Free Method

ozempic without the side effects? try this drug-free method

Losing Weight= Losing Health? Ozempic Risks You Can’t Afford To Ignore

losing weight= losing health? ozempic risks you can’t afford to ignore

Joe Biden Is Diagnosed With Aggressive Prostate Cancer: All That You Need To Know

joe biden is diagnosed with aggressive prostate cancer: all that you need to know

About 2 Out Of 5 Heart Failure Patients Don’t See A Cardiologist Even Once A Year

about 2 out of 5 heart failure patients don’t see a cardiologist even once a year

What if the one injection that is helping you lose weight and manage diabetes also protect you from <span>cancer</span>? That's the surprising promise emerging from a new study on <span>GLP-1 drugs</span>, drugs already drawing attention for their ability to battle obesity and regulate blood sugar. Now scientists have discovered a potential new advantage: a much reduced risk of cancers related to obesity.

While the global use of GLP-1 agonists such as Saxenda and Byetta is gaining speed, this research unlocks a thrilling new era in preventive care. But just how do such medications function and why could they be protecting us against cancer?

After once being touted as miracle drugs for treating obesity and type 2 diabetes, GLP-1 medications such as Saxenda and Byetta are now uncovering a new benefit: a reduced risk of cancer. New research in the journal eClinicalMedicine identifies that these initial weight-loss medications may have more to their credit than just reducing waistlines—they can cut the risk of developing obesity-linked cancers by a dramatic 41%.

This finding has the potential to change forever the way that we think about the wider ramifications of GLP-1 treatments, particularly in a world where metabolic diseases are closely associated with cancer susceptibility. But why might this new benefit exist? And how do these drugs actually work?

<h2>What Are GLP-1 Drugs and How Do They Work?</h2>

GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a type of drug that mimics the effect of an endogenous hormone involved in the modulation of appetite, blood glucose levels, and digestion. Initially approved for the treatment of type 2 diabetes, they've become very popular due to their capacity to cause weight loss by reducing hunger and slowing gastric emptying.

Drugs such as liraglutide (Saxenda) and exenatide (Byetta) are usually given through subcutaneous injection. Newer forms, including semaglutide (<span>Ozempic</span>) and tirzepatide (Zepbound), have greater efficacy in weight loss and metabolic control, although they were not part of this specific study.

GLP-1 acts via a cascade of hormonal action:

<ul><li>It triggers the release of insulin from the pancreas, lowering blood sugar.</li><li>It inhibits the release of glucagon, a hormone that increases blood sugar.</li><li>It reduces the rate at which the stomach empties following meals.</li></ul>

Perhaps most importantly for managing weight, it sends satiety messages to the brain to make people feel fuller for longer.

<h2>Missing Link Between Cancer Risk and Obesity </h2>

Both type 2 diabetes and obesity are firmly established as risk factors for many forms of cancer, such as breast, colon, uterine, pancreatic, and liver cancer. This can be explained by the chronic inflammation, insulin resistance, and hormonal imbalance that accompany excess fat stores.

For their new study, scientists from Clalit Health Services in Tel Aviv, Israel, analyzed electronic health records of more than 6,300 adults age 24 and above. Everyone involved had both type 2 diabetes and obesity and received either GLP-1 medication or weight-loss surgery between 2010 and 2018. The group was followed through to December 2023 to record cancer diagnoses.

During a median follow-up of 7.5 years, approximately 300 individuals developed cancer of the obesity type—predominantly breast (26%), colon (16%), and uterus (15%).

Although bariatric surgery has been the obesity treatment gold standard for decades—and was in turn found to lower cancer risk—scientists discovered obesity-associated cancers were equal in both the surgery and GLP-1 groups. This was unexpected because surgery tends to induce greater and more immediate weight loss.

Still, additional statistical examination found that the GLP-1 medications offered a 41% lower risk of cancerous developments than surgery indicated that their anti-cancer benefit might extend beyond weight loss alone.

<h2>Reason Behind the Anti-Cancer Effect</h2>

According to co-lead researcher Dr. Dror Dicker, who heads the Obesity Clinic at Hasharon Hospital-Rabin Medical Center, the anti-cancer effects of GLP-1 drugs likely stem from multiple mechanisms. “Reducing inflammation, improving insulin sensitivity, and altering cellular growth pathways may all play a role,” he noted in a news release.

While more recent, more powerful GLP-1 medications such as Ozempic and Zepbound were not included in the study, researchers are convinced they may provide even stronger protective effects. However, additional long-term studies are necessary to determine their impacts on cancers that are not related to obesity.

This new evidence indicates a paradigm shift of foundational importance in the way we think about metabolic health interventions. GLP-1 medications could soon be hailed not merely as weight-loss supplements or treatments for diabetes but as prevention against one of the world's most dreaded illnesses.

Nevertheless, prudence is still advisable. Long-term experience with these drugs is lacking, and their side effects, including nausea, gastrointestinal upset, and possible hazards for thyroid tumors, need to be weighed. A boxed warning is now placed on the list of the FDA for some GLP-1 drugs for thyroid C-cell tumors, although this has so far been seen most commonly in animal models.

With the worldwide obesity epidemic on the rise, so is the need to know how drugs such as GLP-1 agonists can change not only waistlines, but also long-term health endpoints. The notion that a single class of medication might lower the risk of cancer in addition to managing blood glucose and reducing appetite is revolutionary.

Additional research, particularly with next-generation GLP-1 drugs, will be necessary to more fully investigate and validate these benefits but for the time being, this study introduces an exhilarating and promising new chapter at the nexus of <span>cancer prevention</span> and obesity treatment.

cancer

glp-1 drugs

cancer prevention

weight loss medication

obesity-related cancer

saxenda study

glp-1 cancer risk

diabetes and cancer

ozempic

What if the one injection that is helping you lose weight and manage diabetes also protect you from cancer? That's the surprising promise emerging from a new study on GLP-1 drugs, drugs already drawing attention for their ability to battle obesity and regulate blood sugar. Now scientists have discovered a potential new advantage: a much reduced risk of cancers related to obesity.While the global use of GLP-1 agonists such as Saxenda and Byetta is gaining speed, this research unlocks a thrilling new era in preventive care. But just how do such medications function and why could they be protecting us against cancer?After once being touted as miracle drugs for treating obesity and type 2 diabetes, GLP-1 medications such as Saxenda and Byetta are now uncovering a new benefit: a reduced risk of cancer. New research in the journal eClinicalMedicine identifies that these initial weight-loss medications may have more to their credit than just reducing waistlines—they can cut the risk of developing obesity-linked cancers by a dramatic 41%.This finding has the potential to change forever the way that we think about the wider ramifications of GLP-1 treatments, particularly in a world where metabolic diseases are closely associated with cancer susceptibility. But why might this new benefit exist? And how do these drugs actually work?What Are GLP-1 Drugs and How Do They Work?GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a type of drug that mimics the effect of an endogenous hormone involved in the modulation of appetite, blood glucose levels, and digestion. Initially approved for the treatment of type 2 diabetes, they've become very popular due to their capacity to cause weight loss by reducing hunger and slowing gastric emptying.Drugs such as liraglutide (Saxenda) and exenatide (Byetta) are usually given through subcutaneous injection. Newer forms, including semaglutide (Ozempic) and tirzepatide (Zepbound), have greater efficacy in weight loss and metabolic control, although they were not part of this specific study.GLP-1 acts via a cascade of hormonal action:It triggers the release of insulin from the pancreas, lowering blood sugar.It inhibits the release of glucagon, a hormone that increases blood sugar.It reduces the rate at which the stomach empties following meals.Perhaps most importantly for managing weight, it sends satiety messages to the brain to make people feel fuller for longer.Missing Link Between Cancer Risk and Obesity Both type 2 diabetes and obesity are firmly established as risk factors for many forms of cancer, such as breast, colon, uterine, pancreatic, and liver cancer. This can be explained by the chronic inflammation, insulin resistance, and hormonal imbalance that accompany excess fat stores.For their new study, scientists from Clalit Health Services in Tel Aviv, Israel, analyzed electronic health records of more than 6,300 adults age 24 and above. Everyone involved had both type 2 diabetes and obesity and received either GLP-1 medication or weight-loss surgery between 2010 and 2018. The group was followed through to December 2023 to record cancer diagnoses.During a median follow-up of 7.5 years, approximately 300 individuals developed cancer of the obesity type—predominantly breast (26%), colon (16%), and uterus (15%).GLP-1 vs. SurgeryAlthough bariatric surgery has been the obesity treatment gold standard for decades—and was in turn found to lower cancer risk—scientists discovered obesity-associated cancers were equal in both the surgery and GLP-1 groups. This was unexpected because surgery tends to induce greater and more immediate weight loss.Still, additional statistical examination found that the GLP-1 medications offered a 41% lower risk of cancerous developments than surgery indicated that their anti-cancer benefit might extend beyond weight loss alone.Reason Behind the Anti-Cancer EffectAccording to co-lead researcher Dr. Dror Dicker, who heads the Obesity Clinic at Hasharon Hospital-Rabin Medical Center, the anti-cancer effects of GLP-1 drugs likely stem from multiple mechanisms. “Reducing inflammation, improving insulin sensitivity, and altering cellular growth pathways may all play a role,” he noted in a news release.While more recent, more powerful GLP-1 medications such as Ozempic and Zepbound were not included in the study, researchers are convinced they may provide even stronger protective effects. However, additional long-term studies are necessary to determine their impacts on cancers that are not related to obesity.Can It Change Cancer Treatment?This new evidence indicates a paradigm shift of foundational importance in the way we think about metabolic health interventions. GLP-1 medications could soon be hailed not merely as weight-loss supplements or treatments for diabetes but as prevention against one of the world's most dreaded illnesses.Nevertheless, prudence is still advisable. Long-term experience with these drugs is lacking, and their side effects, including nausea, gastrointestinal upset, and possible hazards for thyroid tumors, need to be weighed. A boxed warning is now placed on the list of the FDA for some GLP-1 drugs for thyroid C-cell tumors, although this has so far been seen most commonly in animal models.With the worldwide obesity epidemic on the rise, so is the need to know how drugs such as GLP-1 agonists can change not only waistlines, but also long-term health endpoints. The notion that a single class of medication might lower the risk of cancer in addition to managing blood glucose and reducing appetite is revolutionary.Additional research, particularly with next-generation GLP-1 drugs, will be necessary to more fully investigate and validate these benefits but for the time being, this study introduces an exhilarating and promising new chapter at the nexus of cancer prevention and obesity treatment.

glp-1 drugs fight fat, curb appetite and may also reduce cancer risk

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

FDA Greenlights Zevaskyn for Rare Genetic Skin Condition

Quick Stories

COVID-19 Update: 257 Active Cases In India, 2 New Deaths In Mumbai

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection

GLP-1 Drugs Fight Fat, Curb Appetite And May Also Reduce Cancer Risk

Health Conditions A-Z

COVID-19 Update: 257 Active Cases In India, 2 New Deaths In Mumbai

What Is Japanese Walk—The Fitness Trend That Makes You 10 Years Younger

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection